Table 2 Univariate association of CDR1-AS and hsa-miR-7 with MFS in the prognostic cohort.

From: Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer

Clinical parameters

CDR1-AS

hsa-miR-7

n

HR

(95% CI)

P

n

HR

(95% CI)

P

All patients

345

1.02

(0.90–1.16)

0.76

345

1.14

(1.00–1.30)

0.043

Hormone receptor/growth factor expression (RT-qPCR)*

ESR1-negative

120

1.10

(0.83–1.45)

0.50

120

1.03

(0.77–1.37)

0.86

ESR1-positive

225

0.98

(0.84–1.12)

0.31

225

1.21

(1.06–1.38)

0.006

  1. The association of CDR1-AS/hsa-miR-7 expression and MFS in all patients and the patient subgroups based on ESR1 expression is displayed. * Cut-offs for positive and negative hormone receptor/growth factor status were established as previously described56,57. n = number of patients, HR = hazard ratio, CI = confidence interval, and P = p-value. Significant p-values are printed in bold.
Back to article page